- Home
- By Diseases
- Infectious Ophthalmic Diseases
- Epidemic Keratoconjunctivitis (EKC)
Epidemic Keratoconjunctivitis (EKC) is primarily driven by adenoviral agents and is associated with adenovirus D (AdV) which is a non-enveloped double-stranded DNA virus. Protheragen is dedicated to providing innovative epidemic keratoconjunctivitis (EKC) diagnostic and therapeutic development services, including preclinical research and customized solutions.
Epidemic Keratoconjunctivitis (EKC) constitutes an ocular infection of high contagiousness that results from specific factors of aetiological human adenoviruses (HAdV) of special D species types 8, 37, 53, 54, 56, and 64. It presents itself through an acute form of conjunctivitis having severe corneal involvement (corneal conjunctivitis), and the patient presents with symptoms of intense hyperemia, lacrimation, and subepithelial infiltrates (SEIs) within the cornea. These infiltrates can last for years and potentially, lead to visual complications, including blurring of vision, glare, and a feeling of foreign objects within the eyes.
Antiviral Therapy
As of now, no particular antiviral therapy can address adenovirus infections. Antiviral drugs such as ganciclovir and cidofovir have been tested in vitro and in animals, but their effectiveness is of great concern. Deaths caused by toxicity pose limits to their application. Researcher's efforts are directed towards developing new classes of antiviral compounds that would selectively block adenovirus replication without significant side effects.
Immunomodulation
Topical corticosteroid and the calcineurin inhibitors cyclosporin A and tacrolimus have been used to control inflammation in moderation and have shown considerable promise in altering immune functions. Although these agents prove helpful in the therapeutics of chronic SEIs, they must be used cautiously because of numerous side effects. More recent data show that SEIs are significantly reduced with tacrolimus 0.03% compared to baseline levels prior to therapeutics.
Protheragen offers comprehensive services for the development of diagnostics and therapeutics for Epidemic Keratoconjunctivitis (EKC). Our services include:
Protheragen offers customized services tailored to meet the specific needs of our clients. Our team works closely with researchers and developers to design and implement studies that address unique research questions and objectives. If you are interested in our services, please feel free to contact us.
References